James N Topper bought $24k of PHAT
director at Phathom Pharmaceuticals, Inc.. 7,420 shares at an average of $3.30, traded May 13, 2025, filed May 15, 2025.
Score components
- +15RoleDirector
- 0Trade size$24k at market
- +3Relative to holdingsHoldings up 15%
- +8Price context83% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-013134, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 13, 2025 | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +1,120 | $3.16 | $3,543 | 49,323 | May 15, 2025 |
| May 14, 2025 | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +6,300 | $3.32 | $21k | 55,623 | May 15, 2025 |
Related signals
Other insiders at Phathom Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | PHATsell Phathom Pharmaceuticals, Inc. | Robert Charles Breedlove Principal Accounting Officer | $5,573 461 shares | -1% | |
| 15Weak | PHATsell Phathom Pharmaceuticals, Inc. | Robert Charles Breedlove Principal Accounting Officer | $14k 1,692 shares | -3% | |
| 31Weak | PHATbuy Phathom Pharmaceuticals, Inc. | James N Topper director | $15k 3,780 shares | +7% | |
| 50Moderate | Phathom Pharmaceuticals, Inc. | James N Topper director | $153k 48,203 shares | - | |
| 44Moderate | Phathom Pharmaceuticals, Inc. | Asit Parikh director | $25k 10,000 shares | +12% | |
| 22Weak | PHATsell Phathom Pharmaceuticals, Inc. | Molly Henderson CFO and CBO | $17k 3,678 shares | -4% | |
| 44Moderate | Phathom Pharmaceuticals, Inc. | Terrie Curran President and Chief Executive | $126k 19,109 shares | -5% | |
| 36Weak | Phathom Pharmaceuticals, Inc. | Molly Henderson CFO and CBO | $43k 6,583 shares | -7% | |
| 30Weak | Phathom Pharmaceuticals, Inc. | Molly Henderson CFO and CBO | $10k 1,291 shares | -1% | |
| 28Weak | Phathom Pharmaceuticals, Inc. | Azmi Nabulsi Chief Operating Officer | $8,944 1,118 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.